A randomized double-blind placebo-controlled two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease

M
Martin Farlow, MD

Primary Investigator

Overview

The purpose of this study is to test whether an experimental drug is safe and has beneficial effects in people who are at risk for the onset of clinical symptoms of Alzheimer?s disease.

Description

The purpose of this study is to determine the effects of each of the two therapies given separately, each targeting amyloid, on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of Alzheimer's disease.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's disease,1510319288
  • Age: Between 60 Years - 75 Years
  • Gender: All

Inclusion Criteria
Females must be considered post-menopausal and not of child bearing potential
Fluency in, and ability to read, the language in which study assessments are administered
Participant has evidence of adequate functioning
Exclusion Criteria
Any disability that may prevent the participant from completing all study requirements
Current medical or neurological condition that might impact cognition or performance on cognitive assessments
Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk
History of malignancy of any organ system, treated or untreated, within the past 60 months, regardless of whether there is evidence of local recurrence or metastases
History of hypersensitivity to any of the investigational drugs or their excipients/adjuvant, or to drugs of similar chemical classes
Indication for or current treatment with ChEIs and/or another prescription AD treatment
Contraindication or intolerance to MRI or PET investigations

Additional Information:
Participants will be compensated for their participation.

Updated on 20 Nov 2022. Study ID: 1510319288

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center